Drugs / BG-85738
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07746141 | Sep 2026 → Sep 2028 expected | metastatic malignant neoplasm | BeOne Medicines | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BG-85738 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07746141 ↗ |
| Action | Inhibit | “designed to block RAS proteins that are hyperactive.” NCT07746141 ↗ |
| Route | Oral | “Administered orally” NCT07746141 ↗ |